Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eveotox in Upper Limb Spasticity
NCT07242300Phase 3Recruiting
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of JHM03 in Upper limb spasticity, sponsored by Junhemeng Biopharmaceutical. Started Dec 2025; status: recruiting.
02
Drugs
JHM03
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT07242300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242300.